{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T13:10:12Z","timestamp":1648905012719},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.leukres.2010.11.030","type":"journal-article","created":{"date-parts":[[2010,12,29]],"date-time":"2010-12-29T09:15:21Z","timestamp":1293614121000},"page":"575-576","source":"Crossref","is-referenced-by-count":0,"title":["CML: Defining the efficacy of targeted therapy with the TARGET system"],"prefix":"10.1016","volume":"35","author":[{"given":"Jane L.","family":"Liesveld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.11.030_bib0005","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.seminhematol.2010.06.008","article-title":"Stem cell transplant for chronic myeloid leukemia in the imatinib era","volume":"47","author":"Radich","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2010.11.030_bib0010","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.11.030_bib0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.seminhematol.2010.06.001","article-title":"Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?","volume":"47","author":"Fava","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2010.11.030_bib0020","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatininb for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.11.030_bib0025","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.11.030_bib0030","doi-asserted-by":"crossref","first-page":"76a","DOI":"10.1182\/blood.V112.11.76.76","volume":"112","author":"O\u2019Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.11.030_bib0035","first-page":"462a","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"14","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.11.030_bib0085","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.leukres.2010.10.027","article-title":"Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system","volume":"35","author":"Tauchi","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.11.030_bib0045","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12185-009-0263-z","article-title":"Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML study group","volume":"89","author":"Sakai","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2010.11.030_bib0050","article-title":"Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia","author":"Pinilla-Ibarz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.11.030_bib0055","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.11.030_bib0060","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.leukres.2010.11.030_bib0065","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.11.030_bib0070","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3109\/10428194.2010.491135","article-title":"Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents","volume":"51","author":"Kelly","year":"2010","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.leukres.2010.11.030_bib0075","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","author":"Haouala","year":"2010","journal-title":"Blood"},{"issue":"Suppl. 10","key":"10.1016\/j.leukres.2010.11.030_bib0080","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.3816\/CLML.2010.s.001","article-title":"Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective","volume":"10","author":"Jabbour","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610005783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610005783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T02:06:57Z","timestamp":1592186817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610005783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0145212610005783"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.11.030","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}